449 results on '"Rigaudeau AS"'
Search Results
2. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
- Author
-
Leleu, Xavier, Hulin, Cyrille, Lambert, Jerome, Bobin, Arthur, Perrot, Aurore, Karlin, Lionel, Roussel, Murielle, Montes, Lydia, Cherel, Brieuc, Chalopin, Thomas, Slama, Borhane, Chretien, Marie-Lorraine, Laribi, Kamel, Dingremont, Claire, Roul, Christophe, Mariette, Clara, Rigaudeau, Sophie, Calmettes, Claire, Dib, Mamoun, Tiab, Mourad, Vincent, Laure, Delaunay, Jacques, Santagostino, Alberto, Macro, Margaret, Bourgeois, Emmanuelle, Orsini-Piocelle, Frederique, Gay, Julie, Bareau, Benoit, Bigot, Noemie, Vergez, François, Lebreton, Pierre, Tabrizi, Reza, Waultier-Rascalou, Agathe, Frenzel, Laurent, Le Calloch, Ronan, Chalayer, Emilie, Braun, Thorsten, Lachenal, Florence, Corm, Selim, Kennel, Celine, Belkhir, Rakiba, Bladé, Jean-Sebastien, Joly, Bertrand, Richez-Olivier, Valentine, Gardeney, Helene, Demarquette, Helene, Robu-Cretu, Daniela, Garderet, Laurent, Newinger-Porte, Muriel, Kasmi, Amine, Royer, Bruno, Decaux, Olivier, Arnulf, Bertrand, Belhadj, Karim, Touzeau, Cyrille, Mohty, Mohamad, Manier, Salomon, Moreau, Philippe, Avet-Loiseau, Hervé, Corre, Jill, and Facon, Thierry
- Published
- 2024
- Full Text
- View/download PDF
3. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia
- Author
-
Chevallier, Patrice, Leguay, Thibaut, Delord, Marc, Salek, Cyril, Kim, Rathana, Huguet, Françoise, Hicheri, Yosr, Wartiovaara-Kautto, Ulla, Raffoux, Emmanuel, Cluzeau, Thomas, Balsat, Marie, Roth-Guepin, Gabrielle, Tavernier, Emmanuelle, Lepretre, Stephane, Bilger, Karin, Bergugnat, Hugo, Berceanu, Ana, Alexis, Magda, Doubek, Michael, Brissot, Eolia, Hunault-Berger, Mathilde, Lebon, Delphine, Turlure, Pascal, Chantepie, Sylvain, Belhabri, Amine, Wickenhauser, Stefan, Bastie, Jean-Noel, Cacheux, Victoria, Himberlin, Chantal, Banos, Anne, Gardin, Claude, Bonnet, Sarah, Plantier, Isabelle, Pica, Gian Matteo, Escoffre-Barbe, Martine, Boissel, Nicolas, Dombret, Herve, Clappier, Emmanuelle, Rousselot, Philippe, Lebon, Delphine, Charbonnier, Amandine, Assouan, Deborah, Hubert, Amandine, Quint, Marine, Kossi, Fulvia Guenbem, Deruche, Elodie, Hunault, Mathilde, Marie, Céline, Banos, Anne, Robin, Jean-Baptiste, Gay, Julie, Capdupuy, Claudie, Labarrere, Sévérine, Vincent, Edith, Simonet-Boissard, Marion, BeRceanu, Ana, Larosa, Fabrice, Desbrosses, Yohan, Boiteux, Guillaume, Dufour, Vinciane, Tissot, Elise, Braun, Thorsten, Gardin, Pr Claude, Vidal, Valérie, Edouart, Geoffrey, Chantepie, Sylvain, Vilque, Jean-Pierre, Johnson Ansah, Hyacinthe, Lebouvier, Angélique, Zapalovicz, Marie Charlotte, Renault, Léa, Gian Matteo, Pica, Courouau, Alix, Prieur, Fabienne, Dupre, Charlene, Cacheux, Victoria, De Renzis, Benoit, Chaleteix, Carine, Fayard, Amandine, Roy, Gwendoline, Bastie, Jean-Noël, Caillot, Denis, Devaux, Laetitia, Chevallier, Patrice, Lebourgeois, Amandine, Bonnet, Antoine, Peterlin, Pierre, Lok, Anne, Guilllaume, Thierry, Fontaine, Alexis Morice, Turlure, Pascal, Touati, Mohamed, Kennel, Céline, Dmytruck, Natalya, Abraham, Julie, Jaccard, Arnaud, Remenieras, Liliane, Girault, Stéphane, Gourin, Marie Pierre, Penot, Amélie, Moreau, Stéphane, Philipon, Céline, Roche, Delphine, Belhabri, Amine, Gilis, Lila, Virelizier, Nicolas, Michalet, Anne-Sophie, Monfray, Jérémy, Balsat, Marie, Thomas, Xavier, Praire, Aline, Guepin, Gabrielle Roth, Bonmati, Caroline, Moulin, Charline, Jacquet, Caroline, Carpodomi, Anne, Bouillet, Hélène, Carpentier, Odile, Montero, Mélanie, Pires, Aude, Gastaud, Lauris, Gama, Anastasia, Coelle, Céline, Karmout, Sonia, Cluzeau, Thomas, Loschi, Michael, Lechardeur, Jessica, Chokri, Hatroubi, Broussot, Loic, Wickenhauser, Stefan, Waulthier, Agathe, Jourdan, Eric, Scherman, Elodie, Umuhire, Diane, Damiano, Maria Alessandra, Hicheri, Yors, Saillard, Colombe, DʼIncan, Evelyne, Hospital, Marie-Anne, LʼAttention, Jean Laurent, Rabah, Mme Nassima, Cesari, Laura Castillo, Gehlkopf, Eve, Vincent, Laure, Navarro, Robert, Quittet, Philippe, Fegueux, Nathalie, Ceballos, Patrice, Marin, Fanny Baguet, Sabadash, Véra, Alexis, Magda, Ochmann, Marlène, Laboure, Nina Akakelyan, Bembrahmi, Omar, Michel, Olivier, Ouahrawi, Brahim, Brissot, Eolia, Legrand, Olivier, Vekhoff, Anne, Isnard, Françoise, Sa, Sara E., Dombret, Hervé, Raffoux, Emmanuel, Lenguine, Etienne, Rabian, Florence, Lebras, Karine Celli, Fauvaux, Catherine, Leguay, Thibaut, Gros, François-Xavier, Debus, Cazaubiel, Titouan, Melot, Cyril, Dematteis, Valentin, Messina, Antonella, Himberlin, Chantal, Le, Quoc-Hung, Maggi, Lucia, Barre, Martine Escoffre, Moignet, Aline, De Guibert, Sophie, Bernard, Marc, Decaux, Olivier, de la Chapelle, Thierry Lamy, Nimubona, Stanislas, Kadende, Mme Erica, Flavigny, Aloyse, Plantier, Isabelle, Detourmignies, Laurence, Wemeau, Mathieu, Dervite, Isabelle, Dernivoix, Kathy, Camille, Mme, Denizart, Ingrid, Lepretre, Stéphane, Stamatoullas-Bastard, Aspasia, Fontoura, Marie-Laure, Jardin, Fabrice, Menard, Anne-Lise, Camus, Vincent, Lanic, Helene, Contentin, Nathalie, Cardinael, Nathalie, Lemasle-Hue, Emilie, Alani, Mustafa, Lebreton, Pierre, Atia, Youcef, Bilger, Karin, Ledoux, Marie-Pierre, Sonntag, Cécile, Collin, Camille, Tavernier, Emmanuelle, Guyotat, Denis, Soglu, Gilbert, Le Jeune, Caroline, Cornillon, Jérôme, Durieux, Coralie, Lavoué, Céline, Miler, Dorante, Huguet, Françoise, Tavitian, Suzanne, Soldan, Justine, Rousselot, Philippe, Rigaudeau, Sophie, Philippe, Laure, Lambert, Juliette, Besson, Caroline, Cabannes, Aurélie, Longval, Thomas, Taksin, Anne-Laure, Bah, Mariama, BeulayGue, Anaïs, Doubek, Michael, Folber, Frantisek, Hrabovsky, Stepan, Brzonova, Jana, Vejsadova, Hana, Salek, Cyril, Novotova, Elena, Mertova, Jolana, Brzonova, Jana, Vejsadova, Hana, Wartiovaara-Kautto, Ulla, Salonen, Minna, and Vaalas, Saara
- Published
- 2024
- Full Text
- View/download PDF
4. In vivo multiscale analyses of spring viremia of carp virus (SVCV) infection: From model organism to target species.
- Author
-
Sandra Souto, Raquel Lama, Emilie Mérour, Manon Mehraz, Julie Bernard, Annie Lamoureux, Sarah Massaad, Maxence Frétaud, Dimitri Rigaudeau, Jean K Millet, Christelle Langevin, and Stéphane Biacchesi
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Biology (General) ,QH301-705.5 - Abstract
Spring viremia of carp virus (SVCV) has a broad fish host spectrum and is responsible for a disease that generally affects juvenile fishes with a mortality rate of up to 90%. In the absence of treatments or vaccines against SVCV, the search for prophylactic or therapeutic solutions is thus relevant, particularly to identify solutions compatible with mass vaccination. In addition to being a threat to aquaculture and ecosystems, SVCV is a unique pathogen to study virus-host interactions in the zebrafish model. Establishing the first reverse genetics system for SVCV and the design of recombinant SVCV (rSVCV) expressing fluorescent or bioluminescent proteins adds a new dimension for the study of these interactions using innovative imaging techniques. The infection by bath immersion of zebrafish larvae with rSVCV expressing mCherry allows us to define the first SVCV replication sites and the host innate immune responses using different transgenic lines of zebrafish. The fins were found as the main initial sites of infection in both zebrafish and carp, its natural host. Hence, new insights into the physiopathology of SVCV infection have been described. We report that neutrophils are recruited at the sites of infection and persist up to the death of the animal leading to an uncontrolled inflammation correlated with the expression of the pro-inflammatory cytokine IL1β. Tissue damage was observed at the site of initial replication, a likely consequence of virus-induced injury or the pro-inflammatory response. Interestingly, SVCV infection by bath immersion triggers a persistent pro-inflammatory response rather than activation of the antiviral IFN signaling pathway as observed following intravenous injection, highlighting the importance of the route of infection on the progression of pathogenicity. Thus, this model of zebrafish larvae infection by rSVCV offers new perspectives to study in detail virus-host interactions and to discover new prophylactic or therapeutic solutions.
- Published
- 2024
- Full Text
- View/download PDF
5. Interplay between a bacterial pathogen and its host in rainbow trout isogenic lines with contrasted susceptibility to cold water disease
- Author
-
Lee, Bo-Hyung, Quillet, Edwige, Rigaudeau, Dimitri, Dechamp, Nicolas, Duchaud, Eric, Bernardet, Jean-François, Boudinot, Pierre, and Rochat, Tatiana
- Published
- 2023
- Full Text
- View/download PDF
6. Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Domestic Cat, France, 2022
- Author
-
François-Xavier Briand, Florent Souchaud, Isabelle Pierre, Véronique Beven, Edouard Hirchaud, Fabrice Hérault, René Planel, Angélina Rigaudeau, Sibylle Bernard-Stoecklin, Sylvie Van der Werf, Bruno Lina, Guillaume Gerbier, Nicolas Eterradossi, Audrey Schmitz, Eric Niqueux, and Béatrice Grasland
- Subjects
influenza ,highly pathogenic avian influenza virus ,H5N1 ,clade 2.3.4.4b ,cats ,ducks ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
We detected highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus in a domestic cat that lived near a duck farm infected by a closely related virus in France during December 2022. Enhanced surveillance of symptomatic domestic carnivores in contact with infected birds is recommended to prevent further spread to mammals and humans.
- Published
- 2023
- Full Text
- View/download PDF
7. Two functionally distinct heme/iron transport systems are virulence determinants of the fish pathogen Flavobacterium psychrophilum
- Author
-
Yueying Zhu, Delphine Lechardeur, Jean-François Bernardet, Brigitte Kerouault, Cyprien Guérin, Dimitri Rigaudeau, Pierre Nicolas, Eric Duchaud, and Tatiana Rochat
- Subjects
Iron uptake ,TonB-Dependent receptor ,heme ,HmuY family ,nutritional immunity ,bacteroidetes ,Infectious and parasitic diseases ,RC109-216 - Abstract
Bacterial pathogens have a critical impact on aquaculture, a sector that accounts for half of the human fish consumption. Flavobacterium psychrophilum (phylum Bacteroidetes) is responsible for bacterial cold-water disease in salmonids worldwide. The molecular factors involved in host invasion, colonization and haemorrhagic septicaemia are mostly unknown. In this study, we identified two new TonB-dependent receptors, HfpR and BfpR, that are required for adaptation to iron conditions encountered during infection and for virulence in rainbow trout. Transcriptional analyses revealed that their expression is tightly controlled and upregulated under specific iron sources and concentrations. Characterization of deletion mutants showed that they act without redundancy: BfpR is required for optimal growth in the presence of high haemoglobin level, while HfpR confers the capacity to acquire nutrient iron from haem or haemoglobin under iron scarcity. The gene hfpY, co-transcribed with hfpR, encodes a protein related to the HmuY family. We demonstrated that HfpY binds haem and contributes significantly to host colonization and disease severity. Overall, these results are consistent with a model in which both BfpR and Hfp systems promote haem uptake and respond to distinct signals to adapt iron acquisition to the different stages of pathogenesis. Our findings give insight into the molecular basis of pathogenicity of a serious pathogen belonging to the understudied family Flavobacteriaceae and point to the newly identified haem receptors as promising targets for antibacterial development.
- Published
- 2022
- Full Text
- View/download PDF
8. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
- Author
-
Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel
- Published
- 2022
- Full Text
- View/download PDF
9. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
- Author
-
Bobin, Arthur, Kyheng, Maéva, Guidez, Stéphanie, Gruchet-Merouze, Cécile, Richez, Valentine, Duhamel, Alain, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean-Valère, Bourquard, Pascal, Lenain, Pascal, Perrot, Aurore, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Moreau, Philippe, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry, and Leleu, Xavier
- Published
- 2022
- Full Text
- View/download PDF
10. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
- Author
-
Facon, Thierry, Venner, Christopher P., Bahlis, Nizar J., Offner, Fritz, White, Darrell J., Karlin, Lionel, Benboubker, Lotfi, Rigaudeau, Sophie, Rodon, Philippe, Voog, Eric, Yoon, Sung-Soo, Suzuki, Kenshi, Shibayama, Hirohiko, Zhang, Xiaoquan, Twumasi-Ankrah, Philip, Yung, Godwin, Rifkin, Robert M., Moreau, Philippe, Lonial, Sagar, Kumar, Shaji K., Richardson, Paul G., and Rajkumar, S. Vincent
- Published
- 2021
- Full Text
- View/download PDF
11. Sustainable plant-based diets promote rainbow trout gut microbiota richness and do not alter resistance to bacterial infection
- Author
-
David Pérez-Pascual, Ana Elena Pérez-Cobas, Dimitri Rigaudeau, Tatiana Rochat, Jean-François Bernardet, Sandrine Skiba-Cassy, Yann Marchand, Eric Duchaud, and Jean-Marc Ghigo
- Subjects
Rainbow trout ,Gut microbiota ,Sustainable aquaculture diet ,Flavobacterium psychrophilum ,Veterinary medicine ,SF600-1100 ,Microbiology ,QR1-502 - Abstract
Abstract Background Farmed fish food with reduced fish-derived products are gaining growing interest due to the ecological impact of fish-derived protein utilization and the necessity to increase aquaculture sustainability. Although different terrestrial plant proteins could replace fishmeal proteins, their use is associated with adverse effects. Here, we investigated how diets composed of terrestrial vegetal sources supplemented with proteins originating from insect, yeast or terrestrial animal by-products affect rainbow trout (Onchorynchus mykiss) gut microbiota composition, growth performance and resistance to bacterial infection by the fish pathogen Flavobacterium psychrophilum responsible for frequent outbreaks in aquaculture settings. Results We showed that the tested regimes significantly increased gut bacterial richness compared to full vegetal or commercial-like diets, and that vegetal diet supplemented with insect and yeast proteins improves growth performance compared to full vegetal diet without altering rainbow trout susceptibility to F. psychrophilum infection. Conclusion Our results demonstrate that the use of insect and yeast protein complements to vegetal fish feeds maintain microbiota functions, growth performance and fish health, therefore identifying promising alternative diets to improve aquaculture’s sustainability.
- Published
- 2021
- Full Text
- View/download PDF
12. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study.
- Author
-
Decaux, Olivier, Fontan, Jean, Perrot, Aurore, Karlin, Lionel, Touzeau, Cyrille, Schulmann, Samantha, Manier, Salomon, Belhadj, Karim, Trebouet, Adrien, Zunic, Patricia, Schiano De Colella, Jean‐Marc, Castel, Brice, Van De Wyngaert, Zoé, Pica, Gian Matteo, Tiab, Mourad, Kuhnowski, Frédérique, Bouketouche, Malek, Rigaudeau, Sophia, Benramdane, Riad, and Tekle, Christina
- Abstract
Background: IMAGE is a retrospective cohort study of patients enrolled in early access programs (EAPs) in France with relapsed/refractory multiple myeloma (RRMM) receiving isatuximab with pomalidomide and dexamethasone (Isa‐Pd). Methods: Patients aged ≥18 years with RRMM who received ≥1 dose of Isa under the EAPs between July 29, 2019 and August 30, 2020 were included. Effectiveness endpoints included progression‐free survival (PFS) and response rates. Verbatim terms for adverse events (AEs) were coded using the Medical Dictionary for Regulatory Activities and not graded for severity. Results: A total of 294 and 299 patients were included in the effectiveness and safety populations, respectively. IMAGE included patients who received one prior line of treatment (10.2%) and were daratumumab‐refractory (19.1%). At median follow‐up of 14.2 months, median PFS in the effectiveness population was 12.4 months (95% CI 9.0–15.0). Overall response and very good partial response rates were 46.3% and 27.9%, respectively. Subgroup analyses reflected similar results. In the safety population, 26.4% of patients reported at least one AE; the most common any‐grade AE was neutropenia (9.4%). Conclusion: IMAGE demonstrated Isa‐Pd had meaningful effectiveness in median PFS and depth of response and no new safety signals in a real‐world context, consistent with clinical trial results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Chronicle of Research in Legal and Constitutional History in France in 2020
- Author
-
Pierre-Olivier Rigaudeau
- Subjects
History of Law ,KJ2-1040 - Published
- 2021
- Full Text
- View/download PDF
14. High-Resolution, 3D Imaging of the Zebrafish Gill-Associated Lymphoid Tissue (GIALT) Reveals a Novel Lymphoid Structure, the Amphibranchial Lymphoid Tissue
- Author
-
Alf S. Dalum, Aurora Kraus, Shanawaz Khan, Erna Davydova, Dimitri Rigaudeau, Håvard Bjørgen, Adrián López-Porras, Gareth Griffiths, Geert F. Wiegertjes, Erling O. Koppang, Irene Salinas, Pierre Boudinot, and Julien Rességuier
- Subjects
ALT ,GIALT ,gills ,ILT ,immunology ,lymphoid tissue ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The zebrafish is extensively used as an animal model for human and fish diseases. However, our understanding of the structural organization of its immune system remains incomplete, especially the mucosa-associated lymphoid tissues (MALTs). Teleost MALTs are commonly perceived as diffuse and scattered populations of immune cells throughout the mucosa. Yet, structured MALTs have been recently discovered in Atlantic salmon (Salmo salar L.), including the interbranchial lymphoid tissue (ILT) in the gills. The existence of the ILT was only recently identified in zebrafish and other fish species, highlighting the need for in-depth characterizations of the gill-associated lymphoid tissue (GIALT) in teleosts. Here, using 3-D high-resolution microscopy, we analyze the GIALT of adult zebrafish with an immuno-histology approach that reveals the organization of lymphoid tissues via the labeling of T/NK cells with an antibody directed to a highly conserved epitope on the kinase ZAP70. We show that the GIALT in zebrafish is distributed over at least five distinct sub-regions, an organization found in all pairs of gill arches. The GIALT is diffuse in the pharyngeal part of the gill arch, the interbranchial septum and the filaments/lamellae, and structured in two sub-regions: the ILT, and a newly discovered lymphoid structure located along each side of the gill arch, which we named the Amphibranchial Lymphoid Tissue (ALT). Based on RAG2 expression, neither the ILT nor the ALT constitute additional thymi. The ALT shares several features with the ILT such as presence of abundant lymphoid cells and myeloid cells embedded in a network of reticulated epithelial cells. Further, the ILT and the ALT are also a site for T/NK cell proliferation. Both ILT and ALT show structural changes after infection with Spring Viraemia of Carp Virus (SVCV). Together, these data suggest that ALT and ILT play an active role in immune responses. Comparative studies show that whereas the ILT seems absent in most neoteleosts (“Percomorphs”), the ALT is widely present in cyprinids, salmonids and neoteleosts, suggesting that it constitutes a conserved tissue involved in the protection of teleosts via the gills.
- Published
- 2021
- Full Text
- View/download PDF
15. A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia
- Author
-
Milena Kohn, Marc Delord, Maureen Chbat, Amina Guemriche, Fatiha Merabet, Anne-Laure Roupie, Naelle Lombion, Hassan Farhat, Thomas Longval, Aurélie Cabannes-Hamy, Juliette Lambert, Stéphanie Marque-Juillet, Victoria Raggueneau, Jennifer Osman, Marc Spentchian, Sophie Rigaudeau, Philippe Rousselot, and Caroline Besson
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2021
- Full Text
- View/download PDF
16. The EMMY Longitudinal, Cohort Study: Real-World Data to Describe Multiple Myeloma Management and Outcomes as More Therapeutic Options Emerge
- Author
-
Decaux, Olivier, primary, Garlantézec, Ronan, additional, Belhadj-Merzoug, Karim, additional, Macro, Margaret, additional, Frenzel, Laurent, additional, Perrot, Aurore, additional, moreau, Philippe, additional, Royer, Bruno, additional, Caillot, Denis, additional, Leleu, Xavier, additional, Mohty, Mohamad, additional, Karlin, Lionel, additional, Feugier, Pierre, additional, Rigaudeau, Sophie, additional, Fontan, Jean, additional, Sonntag, Cécile, additional, Vincent, Laure, additional, Chalopin, Thomas, additional, Avet-Loiseau, Hervé, additional, Maarouf, Zakaria, additional, Chanaz, Louni, additional, Texier, Nathalie, additional, and Hulin, Cyrille, additional
- Published
- 2024
- Full Text
- View/download PDF
17. Vaccination of carp against SVCV with an oral DNA vaccine or an insect cells-based subunit vaccine
- Author
-
Embregts, C.W.E., Rigaudeau, D., Tacchi, L., Pijlman, G.P., Kampers, L., Veselý, T., Pokorová, D., Boudinot, P., Wiegertjes, G.F., and Forlenza, M.
- Published
- 2019
- Full Text
- View/download PDF
18. SkinEthic™ RHE for in vitro evaluation of skin irritation of medical device extracts
- Author
-
Pellevoisin, Christian, Videau, Christelle, Briotet, Damien, Grégoire, Corinne, Tornier, Carine, Alonso, Alain, Rigaudeau, Anne Sophie, Bouez, Charbel, and Seyler, Nathalie
- Published
- 2018
- Full Text
- View/download PDF
19. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study
- Author
-
Sabine Kayser, Richard F. Schlenk, Delphine Lebon, Martin Carre, Katharina S. Götze, Friedrich Stölzel, Ana Berceanu, Kerstin Schäfer-Eckart, Pierre Peterlin, Yosr Hicheri, Ramy Rahme, Emmanuel Raffoux, Fatiha Chermat, Stefan W. Krause, Walter E. Aulitzky, Sophie Rigaudeau, Richard Noppeney, Celine Berthon, Martin Görner, Edgar Jost, Philippe Carassou, Ulrich Keller, Corentin Orvain, Thorsten Braun, Colombe Saillard, Ali Arar, Volker Kunzmann, Mathieu Wemeau, Maike de Wit, Dirk Niemann, Caroline Bonmati, Carsten Schwänen, Julie Abraham, Ahmad Aljijakli, Stephanie Haiat, Alwin Krämer, Albrecht Reichle, Martina Gnadler, Christophe Willekens, Karsten Spiekermann, Wolfgang Hiddemann, Carsten Müller-Tidow, Christian Thiede, Christoph Röllig, Hubert Serve, Martin Bornhäuser, Claudia D. Baldus, Eva Lengfelder, Pierre Fenaux, Uwe Platzbecker, and Lionel Adès
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic acid. All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. The acute promyelocytic leukemia was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) of the patients were older than 70 years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 days after starting therapy. With a median follow-up of 1.99 years (95% confidence interval: 1.61-2.30 years) 1-year and 2-year overall survival rates were 97% (95% confidence interval: 94-100%) and 95% (95% confidence interval: 91-99%), respectively. Age above 70 years was associated with a significantly shorter overall survival (P
- Published
- 2021
- Full Text
- View/download PDF
20. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
- Author
-
Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V., Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M., Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves–Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J., Lipkin, Steven M., McKay, James D., and Dumontet, Charles
- Published
- 2019
- Full Text
- View/download PDF
21. Gnotobiotic rainbow trout (Oncorhynchus mykiss) model reveals endogenous bacteria that protect against Flavobacterium columnare infection.
- Author
-
David Pérez-Pascual, Sol Vendrell-Fernández, Bianca Audrain, Joaquín Bernal-Bayard, Rafael Patiño-Navarrete, Vincent Petit, Dimitri Rigaudeau, and Jean-Marc Ghigo
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Biology (General) ,QH301-705.5 - Abstract
The health and environmental risks associated with antibiotic use in aquaculture have promoted bacterial probiotics as an alternative approach to control fish infections in vulnerable larval and juvenile stages. However, evidence-based identification of probiotics is often hindered by the complexity of bacteria-host interactions and host variability in microbiologically uncontrolled conditions. While these difficulties can be partially resolved using gnotobiotic models harboring no or reduced microbiota, most host-microbe interaction studies are carried out in animal models with little relevance for fish farming. Here we studied host-microbiota-pathogen interactions in a germ-free and gnotobiotic model of rainbow trout (Oncorhynchus mykiss), one of the most widely cultured salmonids. We demonstrated that germ-free larvae raised in sterile conditions displayed no significant difference in growth after 35 days compared to conventionally-raised larvae, but were extremely sensitive to infection by Flavobacterium columnare, a common freshwater fish pathogen causing major economic losses worldwide. Furthermore, re-conventionalization with 11 culturable species from the conventional trout microbiota conferred resistance to F. columnare infection. Using mono-re-conventionalized germ-free trout, we identified that this protection is determined by a commensal Flavobacterium strain displaying antibacterial activity against F. columnare. Finally, we demonstrated that use of gnotobiotic trout is a suitable approach for the identification of both endogenous and exogenous probiotic bacterial strains protecting teleostean hosts against F. columnare. This study therefore establishes an ecologically-relevant gnotobiotic model for the study of host-pathogen interactions and colonization resistance in farmed fish.
- Published
- 2021
- Full Text
- View/download PDF
22. Identification of a pharyngeal mucosal lymphoid organ in zebrafish and other teleosts: Tonsils in fish?
- Author
-
Resseguier, Julien, primary, Nguyen-Chi, Mai, additional, Wohlmann, Jens, additional, Rigaudeau, Dimitri, additional, Salinas, Irene, additional, Oehlers, Stefan H., additional, Wiegertjes, Geert F., additional, Johansen, Finn-Eirik, additional, Qiao, Shuo-Wang, additional, Koppang, Erling O., additional, Verrier, Bernard, additional, Boudinot, Pierre, additional, and Griffiths, Gareth, additional
- Published
- 2023
- Full Text
- View/download PDF
23. Qualité du droit et régulation économique
- Author
-
Rigaudeau, Pierre-Olivier, primary
- Published
- 2023
- Full Text
- View/download PDF
24. Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Domestic Cat, France, 2022
- Author
-
Briand, François-Xavier, primary, Souchaud, Florent, additional, Pierre, Isabelle, additional, Beven, Véronique, additional, Hirchaud, Edouard, additional, Hérault, Fabrice, additional, Planel, René, additional, Rigaudeau, Angélina, additional, Bernard-Stoecklin, Sibylle, additional, Van der Werf, Sylvie, additional, Lina, Bruno, additional, Gerbier, Guillaume, additional, Eterradossi, Nicolas, additional, Schmitz, Audrey, additional, Niqueux, Eric, additional, and Grasland, Béatrice, additional
- Published
- 2023
- Full Text
- View/download PDF
25. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
- Author
-
Maria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, Ivan Spicka, Rik Schots, Tomasz Wrobel, Gordon Cook, Meral Beksac, Katharine S Gries, Anupa Kudva, Brenda Tromp, Rian Van Rampelbergh, Huiling Pei, Susan Wroblewski, Robin Carson, Maria Delioukina, Darrell White, Clinical sciences, and Hematology
- Subjects
multiple myeloma ,hematology ,intravenous ,oncology ,Pharmacology (medical) ,subcutaneous ,transplant-ineligible ,daratumumab - Abstract
Introduction Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or lenalidomide/dexamethasone (Rd; MAIA) versus standard-of-care regimens for transplant-ineligible newly diagnosed multiple myeloma. In these studies, patients could switch from DARA IV to subcutaneous daratumumab (DARA SC) while receiving daratumumab monotherapy in ALCYONE (as of Cycle 11) or daratumumab plus Rd in MAIA. The phase 3 COLUMBA study demonstrated noninferiority of DARA SC to DARA IV. DARA SC reduced administration time, allowing patients to spend less time in healthcare settings, a relevant practical consideration for patient care in the COVID-19 pandemic/settings of limited healthcare resources. Methods DARA SC 1800 mg was administered every 4 weeks, per approved dosing schedules. We evaluated safety and patient-reported experience (ALCYONE only) among patients who switched from DARA IV to DARA SC. Results Fifty-seven patients in ALCYONE and 135 in MAIA switched to DARA SC. Three (2.2%; MAIA) patients reported injection-site reactions, all of which were mild. No infusion-related reactions occurred with DARA SC. In ALCYONE, >80% of patients preferred DARA SC over DARA IV. Grade 3/4 treatment-emergent adverse events (TEAEs) occurred in 5.3% of patients in ALCYONE and 25.9% in MAIA; one (0.7%; MAIA) patient experienced a TEAE with an outcome of death. Conclusion For transplant-ineligible newly diagnosed multiple myeloma, DARA SC (monotherapy/with Rd) was safe and preferred over DARA IV. ClinicalTrials.gov, NCT02195479/NCT02252172.
- Published
- 2023
26. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Dumontet, Charles, Demangel, Delphine, Galia, Perrine, Karlin, Lionel, Roche, Laurent, Fauvernier, Mathieu, Golfier, Camille, Laude, Marie-Charlotte, Leleu, Xavier, Rodon, Philippe, Roussel, Murielle, Azaïs, Isabelle, Doyen, Chantal, Slama, Borhane, Manier, Salomon, Decaux, Olivier, Pertesi, Maroulio, Beaumont, Marie, Caillot, Denis, Boyle, Eileen M, Cliquennois, Manuel, Cony-Makhoul, Pascale, Doncker, Anne-Violaine, Dorvaux, Véronique, Petillon, Marie Odile, Fontan, Jean, Hivert, Bénédicte, Leduc, Isabelle, Leyronnas, Cécile, Macro, Margaret, Maigre, Michel, Mariette, Clara, Mineur, Philippe, Rigaudeau, Sophie, Royer, Bruno, Vincent, Laure, Mckay, James, Perrial, Emeline, Garderet, Laurent, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Dumontet, Charles, Demangel, Delphine, Galia, Perrine, Karlin, Lionel, Roche, Laurent, Fauvernier, Mathieu, Golfier, Camille, Laude, Marie-Charlotte, Leleu, Xavier, Rodon, Philippe, Roussel, Murielle, Azaïs, Isabelle, Doyen, Chantal, Slama, Borhane, Manier, Salomon, Decaux, Olivier, Pertesi, Maroulio, Beaumont, Marie, Caillot, Denis, Boyle, Eileen M, Cliquennois, Manuel, Cony-Makhoul, Pascale, Doncker, Anne-Violaine, Dorvaux, Véronique, Petillon, Marie Odile, Fontan, Jean, Hivert, Bénédicte, Leduc, Isabelle, Leyronnas, Cécile, Macro, Margaret, Maigre, Michel, Mariette, Clara, Mineur, Philippe, Rigaudeau, Sophie, Royer, Bruno, Vincent, Laure, Mckay, James, Perrial, Emeline, and Garderet, Laurent
- Abstract
Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively infrequent and most series reported in the literature describe a limited number of families. MM rarely occurs in a familial context. MGUS is observed much more commonly, which can in some cases evolve toward full-blown MM. Although recurrent cytogenetic abnormalities have been described in tumor cells of sporadic cases of MM, the pathogenesis of familial MM remains largely unexplained. In order to identify genetic factors predisposing to familial monoclonal gammopathy, the Intergroupe Francophone du Myélome identified 318 families with at least two confirmed cases of monoclonal gammopathy. There were 169 families with parent/child pairs and 164 families with cases in at least two siblings, compatible with an autosomal transmission. These familial cases were compared with sporadic cases who were matched for age at diagnosis, sex and immunoglobulin isotype, with 10 sporadic cases for each familial case. The gender distribution, age and immunoglobulin subtypes of familial cases were unremarkable in comparison to sporadic cases. With a median follow-up of 7.4 years after diagnosis, the percentage of MGUS cases having evolved to MM was 3%. The median overall survival of the 148 familial MM cases was longer than that of matched sporadic cases, with projected values of 7.6 and 16.1 years in patients older and younger than 65 years, respectively. These data suggest that familial cases of monoclonal gammopathy are similar to sporadic cases in terms of clinical presentation and carry a better prognosis.
- Published
- 2023
27. Qualité du droit et régulation économique
- Author
-
Rigaudeau, Pierre-Olivier and Rigaudeau, Pierre-Olivier
- Abstract
Iz cijelog niza protuprimjera proizlazi da kvaliteta zakona prije svega odgovara obliku strogosti koju regulator mora primijeniti na sebe. Formalni procesi za stvaranje ili podržavanje standarda tu su da prisile regulatora da primijeni, u okviru svoje normativne proizvodnje, visok stupanj zahtjeva tako da donesene odluke najbolje provode gospodarski subjekti., From the entire series of counterexamples, it emerges that the quality of the law first of all corresponds to a form of strictness that the regulator must apply to itself. Formal processes for creating or supporting standards are there to force the regulator to apply, within the framework of its normative production, a high level of demands so that economic entities best implement decisions reached.
- Published
- 2023
28. Identification of a pharyngeal mucosal lymphoid organ in zebrafish and other teleosts : Tonsils in fish?
- Author
-
Resseguier, Julien, Nguyen-Chi, Mai, Wohlmann, Jens, Rigaudeau, Dimitri, Salinas, Irene, Oehlers, Stefan H., Wiegertjes, Geert F., Johansen, Finn Eirik, Qiao, Shuo Wang, Koppang, Erling O., Verrier, Bernard, Boudinot, Pierre, Griffiths, Gareth, Resseguier, Julien, Nguyen-Chi, Mai, Wohlmann, Jens, Rigaudeau, Dimitri, Salinas, Irene, Oehlers, Stefan H., Wiegertjes, Geert F., Johansen, Finn Eirik, Qiao, Shuo Wang, Koppang, Erling O., Verrier, Bernard, Boudinot, Pierre, and Griffiths, Gareth
- Abstract
The constant exposure of the fish branchial cavity to aquatic pathogens causes local mucosal immune responses to be extremely important for their survival. Here, we used a marker for T lymphocytes/natural killer (NK) cells (ZAP70) and advanced imaging techniques to investigate the lymphoid architecture of the zebrafish branchial cavity. We identified a sub-pharyngeal lymphoid organ, which we tentatively named "Nemausean lymphoid organ" (NELO). NELO is enriched in T/NK cells, plasma/B cells, and antigen-presenting cells embedded in a network of reticulated epithelial cells. The presence of activated T cells and lymphocyte proliferation, but not V(D)J recombination or hematopoiesis, suggests that NELO is a secondary lymphoid organ. In response to infection, NELO displays structural changes including the formation of T/NK cell clusters. NELO and gill lymphoid tissues form a cohesive unit within a large mucosal lymphoid network. Collectively, we reveal an unreported mucosal lymphoid organ reminiscent of mammalian tonsils that evolved in multiple teleost fish families.
- Published
- 2023
29. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
- Author
-
Janssen Research and Development, Mateos, Maria Victoria, Rigaudeau, Sophie, Basu, Supratik, Špička, Ivan, Schots, Rik, Wrobel, Tomasz, Cook, Gordon, Beksac, Meral, Gries, Katharine S., Kudva, Anupa, Tromp, Brenda, Rampelbergh, Rian Van, Pei, Huiling, Wroblewski, Susan, Carson, Robin, Delioukina, María, White, Darrell, Janssen Research and Development, Mateos, Maria Victoria, Rigaudeau, Sophie, Basu, Supratik, Špička, Ivan, Schots, Rik, Wrobel, Tomasz, Cook, Gordon, Beksac, Meral, Gries, Katharine S., Kudva, Anupa, Tromp, Brenda, Rampelbergh, Rian Van, Pei, Huiling, Wroblewski, Susan, Carson, Robin, Delioukina, María, and White, Darrell
- Abstract
[Introduction]: Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or lenalidomide/dexamethasone (Rd; MAIA) versus standard-of-care regimens for transplant-ineligible newly diagnosed multiple myeloma. In these studies, patients could switch from DARA IV to subcutaneous daratumumab (DARA SC) while receiving daratumumab monotherapy in ALCYONE (as of Cycle 11) or daratumumab plus Rd in MAIA. The phase 3 COLUMBA study demonstrated noninferiority of DARA SC to DARA IV. DARA SC reduced administration time, allowing patients to spend less time in healthcare settings, a relevant practical consideration for patient care in the COVID-19 pandemic/settings of limited healthcare resources., [Methods]: DARA SC 1800 mg was administered every 4 weeks, per approved dosing schedules. We evaluated safety and patient-reported experience (ALCYONE only) among patients who switched from DARA IV to DARA SC., [Results]: Fifty-seven patients in ALCYONE and 135 in MAIA switched to DARA SC. Three (2.2%; MAIA) patients reported injection-site reactions, all of which were mild. No infusion-related reactions occurred with DARA SC. In ALCYONE, >80% of patients preferred DARA SC over DARA IV. Grade 3/4 treatment-emergent adverse events (TEAEs) occurred in 5.3% of patients in ALCYONE and 25.9% in MAIA; one (0.7%; MAIA) patient experienced a TEAE with an outcome of death., [Conclusion]: For transplant-ineligible newly diagnosed multiple myeloma, DARA SC (monotherapy/with Rd) was safe and preferred over DARA IV. ClinicalTrials.gov, NCT02195479/NCT02252172.
- Published
- 2023
30. Investigation of the Genus Flavobacterium as a Reservoir for Fish-Pathogenic Bacterial Species: the Case of Flavobacterium collinsii
- Author
-
Lee, Bo-Hyung, primary, Nicolas, Pierre, additional, Saticioglu, Izzet Burcin, additional, Fradet, Benjamin, additional, Bernardet, Jean-François, additional, Rigaudeau, Dimitri, additional, Rochat, Tatiana, additional, and Duchaud, Eric, additional
- Published
- 2023
- Full Text
- View/download PDF
31. Identification of a new pharyngeal mucosal lymphoid organ in zebrafish and other teleosts: tonsils in fish?
- Author
-
Resseguier, J, primary, Nguyen-Chis, M, additional, Wohlmann, J, additional, Rigaudeau, D, additional, Salinas, I, additional, Oehlers, SH, additional, Wiegertjes, GF, additional, Johansen, FE, additional, Qiao, SW, additional, Koppang, EO, additional, Verrier, B, additional, Boudinot, P, additional, and Griffiths, G, additional
- Published
- 2023
- Full Text
- View/download PDF
32. Identification of a new pharyngeal mucosal lymphoid organ in zebrafish and other teleosts: tonsils in fish?
- Author
-
Resseguier, J., Nguyen-chi, M., Wohlmann, J., Rigaudeau, D., Salinas, I., Oehlers, S.H., Wiegertjes, G.F., Johansen, F.E., Qiao, S.W., Koppang, E.O., Verrier, B., Boudinot, P., and Griffiths, G.
- Published
- 2023
- Full Text
- View/download PDF
33. Investigation of the Genus Flavobacterium as a Reservoir for Fish-Pathogenic Bacterial Species: the Case of Flavobacterium collinsii
- Author
-
Bo-Hyung Lee, Pierre Nicolas, Izzet Burcin Saticioglu, Benjamin Fradet, Jean-François Bernardet, Dimitri Rigaudeau, Tatiana Rochat, and Eric Duchaud
- Subjects
Ecology ,Applied Microbiology and Biotechnology ,Food Science ,Biotechnology - Abstract
Aquaculture has expanded significantly worldwide in the last decades and accounts for half of human fish consumption. However, infectious fish diseases are a major bottleneck for its sustainable development, and an increasing number of bacterial species from diseased fish raise a great concern.
- Published
- 2023
- Full Text
- View/download PDF
34. Data from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
- Author
-
Thierry Facon, Cyrille Hulin, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal, Eric G. Voog, Véronique Dorvaux, Jean-Claude Eisenmann, Damien Roos-Weil, Olivier Fitoussi, Jamile Frayfer, Catherine Humbrecht-Kraut, Olivier Decaux, Sophie Rigaudeau, Frédérique Kuhnowski, Sophie Cereja, Laurent Voillat, Fritz Offner, Anna Schmitt, Philippe Rodon, Jean Fontan, Marie-Lorraine Chrétien, Gérard Lepeu, Karim Belhadj-Merzoug, Marie-Odile Pétillon, Arnaud Jaccard, Murielle Roussel, Pascal Lenain, Pascal Bourquard, Jean-Valère Malfuson, Nathalie Meuleman, Carla Araujo, Mourad Tiab, Brigitte Kolb, Lionel Karlin, François Machuron, Alain Duhamel, Stéphanie Guidez, Valentine Richez, Guillemette Fouquet, and Xavier Leleu
- Abstract
Purpose:Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile.Patients and Methods:IFM2012-03, a phase I multicenter study of KMP weekly in elderly patients with newly diagnosed multiple myeloma (eNDMM), aimed to determine the MTD of carfilzomib. Carfilzomib was given intravenously at 36, 45, 56, and 70 mg/m2/day on days 1, 8, 15, and 22 with melphalan and prednisone, for nine 35-day induction cycles, followed by carfilzomib maintenance for 1 year. Three dose-limiting toxicities (DLT) determined MTD at the lower dose.Results:Thirty eNDMMs were treated, 6 per cohort at 36, 45, and 56 mg/m2 and 12 at 70 mg/m². There was one DLT at 36 mg/m2 (lymphopenia), one at 45 mg/m2 (lysis syndrome), two at 56 mg/m2 (cardiac insufficiency and febrile neutropenia), and two at 70 mg/m2 (vomiting and elevated liver enzymes). The safety profile was acceptable; however, specific attention must be paid to the risk of cardiovascular events, especially for elderly patients. The overall response rate was 93.3%, with 46.6% complete response.Conclusions:The MTD dose of carfilzomib was 70 mg/m2 in this KMP weekly study in eNDMM. Response rates, and especially CR rate, were remarkable in this population, and would benefit from being assessed in a larger-scale study. The IFM2012-03 study demonstrated that the MTD of carfilzomib weekly is 70 mg/m2 in eNDMM, and 56 mg/m2 for patients older than 75 years. Carfilzomib used weekly in combination has a good efficacy and safety profile in eNDMM.
- Published
- 2023
- Full Text
- View/download PDF
35. Supplementary Tables from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
- Author
-
Thierry Facon, Cyrille Hulin, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal, Eric G. Voog, Véronique Dorvaux, Jean-Claude Eisenmann, Damien Roos-Weil, Olivier Fitoussi, Jamile Frayfer, Catherine Humbrecht-Kraut, Olivier Decaux, Sophie Rigaudeau, Frédérique Kuhnowski, Sophie Cereja, Laurent Voillat, Fritz Offner, Anna Schmitt, Philippe Rodon, Jean Fontan, Marie-Lorraine Chrétien, Gérard Lepeu, Karim Belhadj-Merzoug, Marie-Odile Pétillon, Arnaud Jaccard, Murielle Roussel, Pascal Lenain, Pascal Bourquard, Jean-Valère Malfuson, Nathalie Meuleman, Carla Araujo, Mourad Tiab, Brigitte Kolb, Lionel Karlin, François Machuron, Alain Duhamel, Stéphanie Guidez, Valentine Richez, Guillemette Fouquet, and Xavier Leleu
- Abstract
Supplementary tables 1 to 5
- Published
- 2023
- Full Text
- View/download PDF
36. Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
- Author
-
Thierry Facon, Cyrille Hulin, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal, Eric G. Voog, Véronique Dorvaux, Jean-Claude Eisenmann, Damien Roos-Weil, Olivier Fitoussi, Jamile Frayfer, Catherine Humbrecht-Kraut, Olivier Decaux, Sophie Rigaudeau, Frédérique Kuhnowski, Sophie Cereja, Laurent Voillat, Fritz Offner, Anna Schmitt, Philippe Rodon, Jean Fontan, Marie-Lorraine Chrétien, Gérard Lepeu, Karim Belhadj-Merzoug, Marie-Odile Pétillon, Arnaud Jaccard, Murielle Roussel, Pascal Lenain, Pascal Bourquard, Jean-Valère Malfuson, Nathalie Meuleman, Carla Araujo, Mourad Tiab, Brigitte Kolb, Lionel Karlin, François Machuron, Alain Duhamel, Stéphanie Guidez, Valentine Richez, Guillemette Fouquet, and Xavier Leleu
- Abstract
Supplementary Figure 1. Complementary survival curves for the whole cohort (n=30). (A) Event Free Survival (EFR); (B) Time to new treatment (TTNT); (C) Duration of response (DOR). Supplementary Figure 2. Progression Free Survival and Overall Survival according to cytogenetic risk (n=30). (A) PFS according to cytogenetic risk; (B) OS according to cytogenetic risk.
- Published
- 2023
- Full Text
- View/download PDF
37. Identification of a new pharyngeal mucosal lymphoid organ in zebrafish and other teleosts: tonsils in fish?
- Author
-
J Resseguier, M Nguyen-Chis, J Wohlmann, D Rigaudeau, I Salinas, SH Oehlers, GF Wiegertjes, FE Johansen, SW Qiao, EO Koppang, B Verrier, P Boudinot, and G Griffiths
- Abstract
The constant exposure of the fish branchial cavity to aquatic pathogens must have driven local mucosal immune responses to be extremely important for their survival. In this study, we used a universal marker for T lymphocytes/natural killer cells (ZAP70) and advanced imaging techniques to investigate the lymphoid architecture of the zebrafish branchial cavity. We identified a new lymphoid organ, which we tentatively named “Nemausean Lymphoid Organ” (NEMO), situated below the pharynx, and closely associated with gill lymphoid tissues. Besides T/NK cells, NEMO is enriched in plasma/B cells and antigen-presenting cells embedded in a network of reticulated epithelial cells. Presence of activated T cells and lymphocyte proliferation but not V(D)J recombination or hematopoiesis, suggests a function as secondary lymphoid organ. In response to infection, NEMO displays structural changes including the formation of T/NK cells clusters. NEMO and gill lymphoid aggregates form a cohesive unit within a lymphoid network that extends throughout the pharyngo-respiratory area. Collectively, our findings reveal a new mucosal lymphoid organ reminiscent of mammalian tonsils that evolved in fish. Importantly, NEMO could clearly be identified in multiple teleost fish families.One sentence summaryA previously unreported lymphoid organ has been identified within the pharyngo-respiratory tract of the zebrafish, and other teleost fish, providing new insights into the immune system of teleost fish and the evolution of vertebrate immunology.
- Published
- 2023
- Full Text
- View/download PDF
38. Interplay between a bacterial pathogen and its host in rainbow trout isogenic lines with contrasted susceptibility to Cold Water Disease
- Author
-
Bo-Hyung Lee, Edwige Quillet, Dimitri Rigaudeau, Nicolas Dechamp, Eric Duchaud, Jean-François Bernardet, Pierre Boudinot, and Tatiana Rochat
- Subjects
Infectious Diseases ,Immunology ,Microbiology - Abstract
Infectious diseases are a major constraint on aquaculture. Genetic lines with different susceptibilities to diseases are useful models to identify resistance mechanisms to pathogens and to improve prophylaxis. Bacterial cold-water disease (BCWD) caused byFlavobacterium psychrophilumrepresents a major threat for freshwater salmonid farming worldwide. A collection of rainbow trout (Oncorhynchus mykiss) isogenic lines was previously produced from a French domestic population. Here, we compared BCWD resistance phenotypes using a subset of isogenic lines chosen for their contrasted susceptibilities toF. psychrophilum. We applied individual monitoring to document the infection process, including time-course quantification of bacteremia and innate immune response. Strikingly, BCWD resistance was correlated with a lower bacterial growth rate in blood. Several immune genes were expressed at higher levels in resistant fish regardless of infection: the Type II arginase (arg2), a marker for M2 macrophages involved in anti-inflammatory responses and tissue repair, and two Toll-like receptors (tlr2/tlr7), responsible for pathogen detection and inflammatory responses. This study highlights the importance of innate and intrinsic defense mechanisms in determining the outcome ofF. psychrophiluminfections, and illustrates that non-lethal time-course blood sampling for individual monitoring of bacteremia is a powerful tool to resolve within-host pathogen behavior in bacterial fish diseases.
- Published
- 2023
- Full Text
- View/download PDF
39. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study
- Author
-
Charles Dumontet, Delphine Demangel, Perrine Galia, Lionel Karlin, Laurent Roche, Mathieu Fauvernier, Camille Golfier, Marie‐Charlotte Laude, Xavier Leleu, Philippe Rodon, Murielle Roussel, Isabelle Azaïs, Chantal Doyen, Borhane Slama, Salomon Manier, Olivier Decaux, Maroulio Pertesi, Marie Beaumont, Denis Caillot, Eileen M. Boyle, Manuel Cliquennois, Pascale Cony‐Makhoul, Anne‐Violaine Doncker, Véronique Dorvaux, Marie Odile Petillon, Jean Fontan, Bénédicte Hivert, Isabelle Leduc, Cécile Leyronnas, Margaret Macro, Michel Maigre, Clara Mariette, Philippe Mineur, Sophie Rigaudeau, Bruno Royer, Laure Vincent, James Mckay, Emeline Perrial, Laurent Garderet, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Fédération Française pour la Recherche contre le Myélome et les Gammapathies (FFRMG) Institut National Du Cancer, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie
- Subjects
Chromosome Aberrations ,MESH: Humans ,Paraproteinemias ,MESH: Multiple Myeloma ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Hematology ,Prognosis ,Monoclonal Gammopathy of Undetermined Significance ,MESH: Prognosis ,MESH: Paraproteinemias ,MESH: Child ,MESH: Monoclonal Gammopathy of Undetermined Significance ,Humans ,MESH: Chromosome Aberrations ,Child ,Multiple Myeloma - Abstract
International audience; Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively infrequent and most series reported in the literature describe a limited number of families. MM rarely occurs in a familial context. MGUS is observed much more commonly, which can in some cases evolve toward full-blown MM. Although recurrent cytogenetic abnormalities have been described in tumor cells of sporadic cases of MM, the pathogenesis of familial MM remains largely unexplained. In order to identify genetic factors predisposing to familial monoclonal gammopathy, the Intergroupe Francophone du Myélome identified 318 families with at least two confirmed cases of monoclonal gammopathy. There were 169 families with parent/child pairs and 164 families with cases in at least two siblings, compatible with an autosomal transmission. These familial cases were compared with sporadic cases who were matched for age at diagnosis, sex and immunoglobulin isotype, with 10 sporadic cases for each familial case. The gender distribution, age and immunoglobulin subtypes of familial cases were unremarkable in comparison to sporadic cases. With a median follow-up of 7.4 years after diagnosis, the percentage of MGUS cases having evolved to MM was 3%. The median overall survival of the 148 familial MM cases was longer than that of matched sporadic cases, with projected values of 7.6 and 16.1 years in patients older and younger than 65 years, respectively. These data suggest that familial cases of monoclonal gammopathy are similar to sporadic cases in terms of clinical presentation and carry a better prognosis.
- Published
- 2023
- Full Text
- View/download PDF
40. Interplay between a bacterial pathogen and its host in rainbow trout isogenic lines with contrasted susceptibility to Cold Water Disease
- Author
-
Lee, Bo-Hyung, primary, Quillet, Edwige, additional, Rigaudeau, Dimitri, additional, Dechamp, Nicolas, additional, Duchaud, Eric, additional, Bernardet, Jean-François, additional, Boudinot, Pierre, additional, and Rochat, Tatiana, additional
- Published
- 2023
- Full Text
- View/download PDF
41. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study
- Author
-
Dumontet, Charles, primary, Demangel, Delphine, additional, Galia, Perrine, additional, Karlin, Lionel, additional, Roche, Laurent, additional, Fauvernier, Mathieu, additional, Golfier, Camille, additional, Laude, Marie‐Charlotte, additional, Leleu, Xavier, additional, Rodon, Philippe, additional, Roussel, Murielle, additional, Azaïs, Isabelle, additional, Doyen, Chantal, additional, Slama, Borhane, additional, Manier, Salomon, additional, Decaux, Olivier, additional, Pertesi, Maroulio, additional, Beaumont, Marie, additional, Caillot, Denis, additional, Boyle, Eileen M., additional, Cliquennois, Manuel, additional, Cony‐Makhoul, Pascale, additional, Doncker, Anne‐Violaine, additional, Dorvaux, Véronique, additional, Petillon, Marie Odile, additional, Fontan, Jean, additional, Hivert, Bénédicte, additional, Leduc, Isabelle, additional, Leyronnas, Cécile, additional, Macro, Margaret, additional, Maigre, Michel, additional, Mariette, Clara, additional, Mineur, Philippe, additional, Rigaudeau, Sophie, additional, Royer, Bruno, additional, Vincent, Laure, additional, Mckay, James, additional, Perrial, Emeline, additional, and Garderet, Laurent, additional
- Published
- 2023
- Full Text
- View/download PDF
42. Les empêchements au mariage au Moyen Âge : points de vue croisés
- Author
-
Sarah Rigaudeau
- Published
- 2021
- Full Text
- View/download PDF
43. Implementation, availability and regulatory status of an OECD accepted Reconstructed Human Epidermis model in Brazil
- Author
-
Rodrigo De Vecchi, Vanja Dakic, Guilherme Mattos, Anne-Sophie Rigaudeau, Veronica Oliveira, Cristina Garcia, Nathalie Alépée, José Cotovio, and Charbel Bouez
- Subjects
Reconstructed Human Epidermis ,SkinEthic™ RHE ,Preclinical In Vitro Testing ,Alternative Methods ,Skin Irritation ,Corrosion ,Public aspects of medicine ,RA1-1270 - Abstract
Introduction: In 2014, Brazil has joined the growing list of countries to ban cosmetic products from being tested on animal models. The new legislation comes into force in 2019. As a result, the interest for validated alternative testing methods for safety assessment has been increasing in academia, industry and associations. However, the lack of specific legislation on the use of biological material of human origin for toxicological tests makes the access to alternative in vitro models difficult. Furthermore, importation to Brazil is not possible on timely manner. Method: In this article, we report the implementation process of a Reconstructed Human Epidermis (SkinEthic™ RHE), an alternative model internationally accepted by OECD, through a technology transfer from EPISKIN® Lyon to Brazil. Regulatory evolution has been motivating the implementation and wide use of alternative methods to animal testing in several industry segments including cosmetic and pharmaceutical. Results: Protocol has been shown to be robust and highly reproducible. Quality control parameters (histological analysis, barrier function test and tissue viability) were performed on 24 batches assembled in Brazil. SkinEthic™ RHE model use allows the full replacement of animal test methods for skin hazards identification. It has regulatory acceptance for several toxicological endpoints, such as the Draize test for skin irritation and corrosion. It allows the reduction and refining of pre-clinical protocols through tiered strategies. Implementation of SkinEthic™ RHE protocol is just a first and important step towards a new approach of toxicological safety testing in Brazil. Conclusion: The implementation was successfully done and reported here. However, in order to follow completely the new legislation up to 2019, the availability of validated models is essential. Quality control tests done on RHE batches produced in Brazil demonstrate that the model met OECD acceptance criteria and therefore can be used for reliable prediction of irritation and corrosion classification.
- Published
- 2018
- Full Text
- View/download PDF
44. Intramuscular DNA Vaccination of Juvenile Carp against Spring Viremia of Carp Virus Induces Full Protection and Establishes a Virus-Specific B and T Cell Response
- Author
-
Carmen W. E. Embregts, Dimitri Rigaudeau, Tomáš Veselý, Dagmar Pokorová, Niels Lorenzen, Jules Petit, Armel Houel, Malte Dauber, Heike Schütze, Pierre Boudinot, Geert F. Wiegertjes, and Maria Forlenza
- Subjects
DNA vaccination ,spring viremia of carp virus ,T cells ,B cells ,rhabdovirus ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Although spring viremia of carp virus (SVCV) can cause high mortalities in common carp, a commercial vaccine is not available for worldwide use. Here, we report a DNA vaccine based on the expression of the SVCV glycoprotein (G) which, when injected in the muscle even at a single low dose of 0.1 µg DNA/g of fish, confers up to 100% protection against a subsequent bath challenge with SVCV. Importantly, to best validate vaccine efficacy, we also optimized a reliable bath challenge model closely mimicking a natural infection, based on a prolonged exposure of carp to SVCV at 15°C. Using this optimized bath challenge, we showed a strong age-dependent susceptibility of carp to SVCV, with high susceptibility at young age (3 months) and a full resistance at 9 months. We visualized local expression of the G protein and associated early inflammatory response by immunohistochemistry and described changes in the gene expression of pro-inflammatory cytokines, chemokines, and antiviral genes in the muscle of vaccinated fish. Adaptive immune responses were investigated by analyzing neutralizing titers against SVCV in the serum of vaccinated fish and the in vitro proliferation capacity of peripheral SVCV-specific T cells. We show significantly higher serum neutralizing titers and the presence of SVCV-specific T cells in the blood of vaccinated fish, which proliferated upon stimulation with SVCV. Altogether, this is the first study reporting on a protective DNA vaccine against SVCV in carp and the first to provide a detailed characterization of local innate as well as systemic adaptive immune responses elicited upon DNA vaccination that suggest a role not only of B cells but also of T cells in the protection conferred by the SVCV-G DNA vaccine.
- Published
- 2017
- Full Text
- View/download PDF
45. Investigation of the genus Flavobacterium as a reservoir for fish-pathogenic bacterial species: the case of Flavobacterium collinsii
- Author
-
Bo-Hyung Lee, Pierre Nicolas, Izzet Burcin Saticioglu, Benjamin Fradet, Jean-François Bernardet, Dimitri Rigaudeau, Tatiana Rochat, and Eric Duchaud
- Abstract
Bacteria of the genus Flavobacterium are recovered from a large variety of environments. Among the described species, Flavobacterium psychrophilum and Flavobacterium columnare are causing considerable losses in fish farms. Alongside these well-known fish-pathogenic species, isolates belonging to the same genus recovered from diseased or apparently healthy wild, feral, and farmed fish have been suspected to be pathogenic. Here, we report the identification and genomic characterization of a F. collinsii isolate (TRV642) retrieved from rainbow trout spleen. A phylogenetic tree of the genus built by aligning the core genome of 195 Flavobacterium species revealed that F. collinsii is standing within a cluster of species associated to diseased fish, the closest one being F. tructae which was recently confirmed as pathogenic. We evaluated the pathogenicity of F. collinsii TRV642 as well as of F. bernardetii F-372T, another recently described species reported as a possible emerging pathogen. Following intramuscular injection challenges in rainbow trout, no clinical signs nor mortalities were observed. However, F. collinsii was isolated from the internal organs of wounded fish, suggesting that the bacterium could invade fish under compromised conditions such as stress and/or wounds. Our results suggest that some fish-associated Flavobacterium species should be considered as opportunistic fish pathogens causing disease under specific circumstances.IMPORTANCEAquaculture has expanded significantly worldwide in the last decades and accounts for half of human fish consumption. However, infectious fish diseases are a major bottleneck for its sustainable development and an increasing number of bacterial species from diseased fish raise a great concern. The current study revealed phylogenetic associations with ecological niches among the Flavobacterium species. We also focused on Flavobacterium collinsii that belongs to a group of putative pathogenic species. The genome contents revealed a versatile metabolic repertoire suggesting the use of diverse nutrient sources, a characteristic of saprophytic or commensal bacteria. In a rainbow trout experimental challenge, the bacterium colonized only oppressed fish facing stressful conditions suggesting opportunistic pathogenic behavior. This study highlights the importance of experimentally evaluating the pathogenicity of the numerous bacterial species retrieved from diseased fish.
- Published
- 2022
- Full Text
- View/download PDF
46. Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
- Author
-
Bobin, Arthur, primary, Lambert, Jerome, additional, Perrot, Aurore, additional, Manier, Salomon, additional, Montes, Lydia, additional, Jaccard, Arnaud, additional, Karlin, Lionel, additional, Godmer, Pascal, additional, Caillot, Denis, additional, Hulin, Cyrille, additional, Chalopin, Thomas, additional, Roul, Christophe, additional, Mariette, Clara, additional, Rigaudeau, Sophie, additional, Dingremont, Claire, additional, Santagostino, Alberto, additional, Dib, Mamoun, additional, Macro, Margaret, additional, Tiab, Mourad, additional, Laribi, Kamel, additional, Bourgeois-Petit, Emmanuelle, additional, Calmettes, Claire, additional, Orsini, Frederique, additional, Tabrizi, Reza, additional, Vincent, Laure, additional, Mohty, Mohamad, additional, Touzeau, Cyrille, additional, Corre, Jill, additional, Moreau, Philippe, additional, Facon, Thierry, additional, Avet Loiseau, Herve, additional, and Leleu, Xavier, additional
- Published
- 2022
- Full Text
- View/download PDF
47. Investigation of the genus Flavobacterium as a reservoir for fish-pathogenic bacterial species: the case of Flavobacterium collinsii
- Author
-
Lee, Bo-Hyung, primary, Nicolas, Pierre, additional, Saticioglu, Izzet Burcin, additional, Fradet, Benjamin, additional, Bernardet, Jean-François, additional, Rigaudeau, Dimitri, additional, Rochat, Tatiana, additional, and Duchaud, Eric, additional
- Published
- 2022
- Full Text
- View/download PDF
48. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
- Author
-
Mateos, Maria-Victoria, primary, Rigaudeau, Sophie, additional, Basu, Supratik, additional, Spicka, Ivan, additional, Schots, Rik, additional, Wrobel, Tomasz, additional, Cook, Gordon, additional, Beksac, Meral, additional, Gries, Katharine S, additional, Kudva, Anupa, additional, Tromp, Brenda, additional, Van Rampelbergh, Rian, additional, Pei, Huiling, additional, Wroblewski, Susan, additional, Carson, Robin, additional, Delioukina, Maria, additional, and White, Darrell, additional
- Published
- 2022
- Full Text
- View/download PDF
49. Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis
- Author
-
Ghez, David, Micol, Jean-Baptiste, Pasquier, Florence, Auger, Nathalie, Saada, Véronique, Spentchian, Marc, Ianotto, Jean-Christophe, Bourhis, Jean-Henri, Bennaceur-Griscelli, Anelyse, Terré, Christine, Castaigne, Sylvie, Rigaudeau, Sophie, Rousselot, Philippe, and de Botton, Stéphane
- Published
- 2013
- Full Text
- View/download PDF
50. Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
- Author
-
Bobin, Arthur, Lambert, Jerome, Perrot, Aurore, Manier, Salomon, Montes, Lydia, Jaccard, Arnaud, Karlin, Lionel, Godmer, Pascal, Caillot, Denis, Hulin, Cyrille, Chalopin, Thomas, Roul, Christophe, Mariette, Clara, Rigaudeau, Sophie, Dingremont, Claire, Santagostino, Alberto, Dib, Mamoun, Macro, Margaret, Tiab, Mourad, Laribi, Kamel, Bourgeois-Petit, Emmanuelle, Calmettes, Claire, Orsini, Frederique, Tabrizi, Reza, Vincent, Laure, Mohty, Mohamad, Touzeau, Cyrille, Corre, Jill, Moreau, Philippe, Facon, Thierry, Avet Loiseau, Herve, and Leleu, Xavier
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.